Sergey Efuni, MD, PhD

Dr. Sergey Efuni has extensive experience in academia, as well as in clinical practice in the therapeutic areas of immunology/allergy, oncology, cardiology, and endocrinology, among others. Dr. Efuni has managed phase 1 to 4 clinical trials in advanced solid tumors and hematologic malignancies, chronic inflammation, allergic disorders, and neurology. He has a track record of submissions/marketing approvals with the US FDA and European Medicines Agency, including mogamulizumab (POTELIGEO) for CTCL/Cezary and istradefylline (NOURIANZ) for Parkinson’s disease (2019). Dr. Efuni received the President Award in 2018 with Kyowa Kirin and was a speaker and clinical investigator for Novo Nordisk, Sanofi, and Ely Lilly.